SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Ubiquitination governs oscillation of cyclin-dependent kinase (CDK) activity through a periodic degradation of cyclins for orderly cell cycle progression; however, the mechanism that maintains the constant CDK protein levels throughout the cell cycle remains unclear. Here we show that CDK6 is modified by small ubiquitin-like modifier-1 (SUMO1) in glioblastoma, and that CDK6 SUMOylation stabilizes the protein and drives the cell cycle for the cancer development and progression. CDK6 is also a substrate of ubiquitin; however, CDK6 SUMOylation at Lys 216 blocks its ubiquitination at Lys 147 and inhibits the ubiquitin-mediated CDK6 degradation. Throughout the cell cycle, CDK1 phosphorylates the SUMO-specific enzyme, ubiquitin-conjugating enzyme9 (UBC9) that in turn mediates CDK6 SUMOylation during mitosis; CDK6 remains SUMOylated in G1 phase and drives the cell cycle through G1/S transition. Thus, SUMO1–CDK6 conjugation constitutes a mechanism of cell cycle control and inhibition of this SUMOylation pathway may provide a strategy for treatment of glioblastoma. The correct timing of cyclin-dependent kinase (CDK) activity is crucial for the fidelity of the cell cycle. In this study, Bellail et al.show that CDK6 protein levels are positively regulated by SUMOylation and that this modification blocks ubiquitination and subsequent degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundSpecific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundMammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundMouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundPuyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundThe Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundBrotherton, D. H., Dhanaraj, V., Wick, S., Brizuela, L., Domaille, P. J., Volyanik, E., Xu, X., Parisini, E., Smith, B. O., Archer, S. J., et al. (1998) · Nature · doi:10.1038/26164 · Cited by 210 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundTherapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
Bellail, A. C., Olson, J. J., Yang, X., Chen, Z. J., & Hao, C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0172 · Cited by 113 · cited 1×
“Chen (University of Texas Southwestern Medical center, TX) for kindly providing the plasmid YFP-SUMO1∆C4 (1-97), YFP-SUMO3∆C11, pcDNA3 6xHis/SUMO1, pCMV-myc-UBC9, pEF-IRES-P-HA-UbK48, pEF-IRES-P-HA-Ub-K0, pEF-IRES-P-HA-Ub-WT and pEF-IRES-P-HA-R48.”
BackgroundSelf-citation
Cited by
Proteogenomic and metabolomic characterization of human glioblastoma
Wang, L.-B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.006 · Cited by 661
SUMO and the robustness of cancer
Seeler, J.-S., & Dejean, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.143 · Cited by 429
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
The post-translational modification, SUMOylation, and cancer (Review)
Han, Z.-J., Feng, Y.-H., Gu, B.-H., Li, Y.-M., & Chen, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4280 · Cited by 334
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer
Eifler, K., & Vertegaal, A. C. O. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.006 · Cited by 290
Metadata
- Authors
- Bellail, A. C., Olson, J. J., & Hao, C.
- Venue
- Nature Communications
- Published
- 2014-06-23
- Volume
- 5
- Issue
- 1
- Pages
- 4234-4234
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2041299849
- Cited by
- 122
- References
- 16
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.